Chemical engineers boost bacteria’s productivity

| February 13, 2017

article image
MIT chemical engineers have designed a novel genetic switch that allows them to dramatically boost bacteria’s production of useful chemicals by shutting down competing metabolic pathways in the cells. In a paper appearing in the Feb. 13 issue of Nature Biotechnology, the researchers showed that they could significantly enhance the yield of glucaric acid, a chemical that is a precursor to products such as nylons and detergents. This genetic switch could also be easily swapped into bacteria that generate other products, the researchers say.

Spotlight

Kameda Arabia

Kameda Arabia (KA) is a Joint Venture between Dr. Soliman Fakeeh Holding company, Jeddah and Kameda Infologics Pvt Ltd based in Japan, India and local support offices in USA, UK, UAE and Malaysia. Dr. Soliman Fakeeh is a renowned name in the Saudi Arabia Healthcare Market from past three decade. Having its Business in Healthcare, Education, Medical Item Supply's and Wellness. Kameda Infologics Pvt Ltd (KI) is a provider of integrated IT solutions to the healthcare industry and has strived to develop world-class software products specializing in Healthcare. Dr. Toshitada Kameda, founder of Kameda Informatics Ltd. is a pioneer in the development of paperless solutions and is currently rendering its service to more than 200 hospitals in Japan. It was Dr. Kameda’s vision which made Kameda Medical Center a 1000 bedded super specialty hospital, south of Tokyo, into a paperless and filmless facility since 1994. KI is using the best practices, systems and quality procedures for its software de

OTHER ARTICLES

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Spotlight

Kameda Arabia

Kameda Arabia (KA) is a Joint Venture between Dr. Soliman Fakeeh Holding company, Jeddah and Kameda Infologics Pvt Ltd based in Japan, India and local support offices in USA, UK, UAE and Malaysia. Dr. Soliman Fakeeh is a renowned name in the Saudi Arabia Healthcare Market from past three decade. Having its Business in Healthcare, Education, Medical Item Supply's and Wellness. Kameda Infologics Pvt Ltd (KI) is a provider of integrated IT solutions to the healthcare industry and has strived to develop world-class software products specializing in Healthcare. Dr. Toshitada Kameda, founder of Kameda Informatics Ltd. is a pioneer in the development of paperless solutions and is currently rendering its service to more than 200 hospitals in Japan. It was Dr. Kameda’s vision which made Kameda Medical Center a 1000 bedded super specialty hospital, south of Tokyo, into a paperless and filmless facility since 1994. KI is using the best practices, systems and quality procedures for its software de

Events